HDLs and the pathogenesis of atherosclerosis

Area of Science:

• Cardiovascular Biology
• Atherosclerosis Research
• Lipid Metabolism

Background:

• High-density lipoprotein (HDL) cholesterol levels indicate cardiovascular health but are not a direct therapeutic target.
• HDL particles possess anti-atherosclerotic properties, including cholesterol efflux, vasodilation, and anti-inflammatory effects, independent of cholesterol content.
• In aging and disease, HDL functionality diminishes due to modifications in its proteome and lipidome.

Purpose of the Study:

• To investigate the role of desmocollin 1 (DSC1) in the loss of HDL function during atherosclerosis.
• To explore the 'apoA-I retention hypothesis' regarding DSC1's mechanism in inhibiting HDL's atheroprotective effects.

Main Methods:

• Analysis of HDL components and their functional effects.
• Investigating the interaction between DSC1 and apolipoprotein A-I (apoA-I) in atherosclerotic plaques.
• Evaluating the impact of DSC1 expression on HDL function in disease models.

Main Results:

• Desmocollin 1 (DSC1) is identified as an apolipoprotein A-I (apoA-I) binding protein highly expressed in atherosclerotic plaques.
• DSC1 retains apoA-I within macrophages, inhibiting the beneficial functions of HDL.
• This DSC1-mediated apoA-I retention is proposed as a mechanism contributing to atherosclerosis.

Conclusions:

• HDL loses its beneficial properties in aging and disease states.
• Desmocollin 1 (DSC1) plays a critical role in impairing HDL function by retaining apoA-I.
• Targeting novel pathways, such as the DSC1-apoA-I interaction, may offer new therapeutic strategies to restore HDL function and combat atherosclerosis.